Is there a role for agomelatine in the treatment of anxiety disorders? A review of published data

International Journal of Immunopathology and Pharmacology

Volumn 26, Issue 2, 2013, Pages 299-304

  De Berardis, D ^a,b   Conti, C M ^b   Marini, S ^a,b   Ferri, F ^a   Iasevoli, F ^c   Valchera, A ^d   Fornaro, M ^e   Cavuto, M ^f   Srinivasan, V ^g   Perna, G ^h,i,j   Carano, A ^k   Piersanti, M ^l   Martinotti, G ^b   Di Giannantonio, M ^b  

^a G Mazzini Hospital   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Hermanas Hospitalarias   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f IASM   (Italy)

^g Sri Sathya Sai Medical Educational and Research Foundation   (India)

^h Department of Clinical Neurosciences ^*  (Italy)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j MAASTRICHT UNIVERSITY   (Netherlands)

^k Hospital CG Mazzoni Ascoli Piceno   (Italy)

^l Pharmacy Hospital   (Italy)

more..

Author keywords

Agomelatine; Anxiety disorders; Dopamine; Efficacy; Melatonin; Noradrenaline; Serotonin; Tolerability

Indexed keywords

AGOMELATINE; CYTOCHROME P450 2C9; PLACEBO;

ANXIETY DISORDER; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; GENERALIZED ANXIETY DISORDER; HUMAN; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; DISABILITY; INSOMNIA; OBSESSIVE COMPULSIVE DISORDER; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SOCIAL PHOBIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

EID: 84881247113     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201302600203     Document Type: Review

References (30)

1. De Berardis D, Campanella D, Serroni N, et al. The impact of alexithymia on anxiety disorders: A review of the literature. Curr Psychiatry Rev 2008; 4:80-6. (Pubitemid 352024822)
2. Conti CM, Fulcheri M, Anogeianaki A, et al. Psychological stress and vitamins. J Biol Regul Homeost Agents 2011; 25:163-8.
3. Conti CM, Fulcheri M. Interrelationship between psychology and cytokines. J Biol Regul Homeost Agents 2010; 24:485-90.
4. De Berardis D, Conti CM, Serroni N, et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol 2010; 23:417-22.
5. André C. Anxiety and circadian rhythms. Encephale 2009; 35:76-9.
6. Srinivasan V, Pandi-Perumal SR, Trahkt I, Spence DW, Poeggeler B, Hardeland R, Cardinali DP. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci 2009; 119:821-46.
7. Martinotti G, Sepede G, Gambi F, et al. Agomelatine versus Venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol 2012; 32:487-91.
8. Di Giannantonio M, Di Iorio G, Guglielmo R, De Berardis D, Conti CM, Acciavatti T, Cornelio M, Martinotti G. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents 2011; 25:109-14.
9. De Berardis D, Di Iorio G, Acciavatti T, et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 2011; 10:119-32.
10. Racagni G, Riva MA, Molteni R, Musazzi L, Calabrese F, Popoli M, Tardito D. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry 2011; 12:574-87.
11. Srinivasan V, De Berardis D, Shillcott SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs 2012, in press.
12. Gruca P, Przegalinski E, Mrowiec S, Lason M, Papp M. Evidence for antidepressant and anxiolytic-like activities of melatonin and agomelatine in animal models. Eur Neuropsychopharmacol 2004; 14:S230.
13. De Berardis D, Acciavatti T, Di Iorio G, et al. The melatonergic system: effects on sleep and implications for the treatment of psychiatric disorders. ChronoPhysiology and Therapy 2011; 1:59-67.
14. Gambi F, De Berardis D, Sepede G, et al. Effect of mirtazapine on thyroid hormones in adult patients with major depression. Int J Immunopathol Pharmacol 2005; 18:737-44.
15. Gambi F, De Berardis D, Campanella D, et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol 2005; 19:483-7. (Pubitemid 41392302)
16. Tardito D, Milanese M, Bonifacino T, et al. Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways. BMC Neurosci 2010; 11:68.
17. Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010; 8:287-304.
18. Li X, Borjigin J, Snyder SH. Molecular rhythms in the pineal gland. Curr Opin Neurobiol 1998; 8:648-51. (Pubitemid 28488427)
19. Naguib M, Samarkandi AH. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: a double-blinded, placebo-controlled study. Anesth Analg 2000; 91:473-9. (Pubitemid 30624319)
20. Karakaş A, Coşkun H, Kaya A, Kücük A, Gündüz B. The effects of the intraamygdalar melatonin injections on the anxiety like behavior and the spatial memory performance in male Wistar rats. Behav Brain Res 2011; 222:141-50.
21. Cheng XP, Sun H, Ye ZY, Zhou JN. Melatonin modulates the GABAergic response in cultured rat hippocampal neurons. J Pharmacol Sci 2012; 119:177-85.
22. Lôo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17:239-47.
23. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28:561-6.
24. Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 2012; 73:1002-8.
25. Fornaro M. Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Ann Gen Psychiatry 2011; 10:5.
26. da Rocha FF, Correa H. Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD. Clin Neuropharmacol 2011; 34:139-40.
27. De Berardis D, Serroni N, Campanella D, Olivieri L, Moschetta FS, Conti CM, Conti P, Di Giannantonio M. A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy. J Clin Psychopharmacol 2012; 32:289-90.
28. Fornaro M. Agomelatine in the treatment of panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:286-7.
29. Crippa JA, Hallak JE, Zuardi AW, Chagas MH, Quevedo J, Nardi AE. Agomelatine in the treatment of social anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1357-8.
30. De Berardis D, Serroni N, Marini S, Moschetta FS, Martinotti G, Di Giannantonio M. Agomelatine for the treatment of posttraumatic stress disorder: A case report. Ann Clin Psychiatry 2012; 24:241-2.